Andrew J. Armstrong, MD, MSc
- Medicine / Medicine - Oncology
- Surgery / Vascular
Address
DUMC 102002
Durham, NC 27710
Appointment Telephone
919-668-8108
Office Telephone
919-668-4667
Fax Telephone
919-660-0178
- MD, University of Virginia School of Medicine, 2000
- Internal Medicine, Hospital of the University of Pennsylvania, 2000-2003
- Medical Oncology, Johns Hopkins Hospital (Maryland), 2003-2006
- MSc, Clinical Investigation, Johns Hopkins School of Public Health (Maryland), 2007
Clinical Interests
Drug development and novel strategies for the treatment and management of advanced prostate cancer and other GU malignancies; targeted therapy; PI3 kinase inhibitor; novel hormonal and immune therapies; targeted therapies; predictive biomarkers; prognostic and surrogate models in GU malignancies; perioperative biologic therapeutics; circulating tumor-cell biology
Research Interests
1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. PI3 kinase/mTOR inhibition in prostate cancer: mechanisms of sensitivity and resistance
7. Developing prognostic models for progression and survival in metastatic prostate cancer
8. Examining surrogate markers of mortality in metastatic prostate cancer
9. Clear cell and non-clear cell renal cell carcinoma: natural history, sensitivity to novel agents including mTOR and VEGF inhibition
This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
- Active Biotech/IPSEN
- Bayer
- Becton, Dickinson and Company
- Bristol Myers Squibb
- Decision Resources, Inc.
- Dendreon Corporation
- Double Helix
- Gerson Lehrman Group, Inc.
- GlaxoSmithKline
- Guidepoint Global
- Kanglaite
- Kohl's Corporation
- LEK Consulting LLC
- Medivation, Inc.
- Novartis
- Pfizer Inc.
- Platform Q
- SSRP
- Science Branding Communications
- Seattle Genetics
- Veridex, LLC (Janssen)
- sanofi aventis
Representative Publications
Whang, YE; Armstrong, AJ; Rathmell, WK; Godley, PA; Kim, WY; Pruthi, RS; Wallen, EM; Crane, JM; Moore, DT; Grigson, G; Morris, K; Watkins, CP; George, DJ. A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Urologic Oncology: seminars and original investigations. 2013;31:82-86.
(2013)
Abstract
Araujo, JC; Mathew, P; Armstrong, AJ; Braud, EL; Posadas, E; Lonberg, M; Gallick, GE; Trudel, GC; Paliwal, P; Agrawal, S; Logothetis, CJ. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer. 2012;118:63-71.
(2012)
Abstract
Armstrong, AJ; Eisenberger, MA; Halabi, S; Oudard, S; Nanus, DM; Petrylak, DP; Sartor, AO; Scher, HI. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. European Urology. 2012;61:549-559.
(2012)
Abstract
Pond, GR; Armstrong, AJ; Wood, BA; Brookes, M; Leopold, L; Berry, WR; de Wit, R; Eisenberger, MA; Tannock, IF; Sonpavde, G. Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. European Urology. 2012;61:363-369.
(2012)
Abstract
Sonpavde, G; Pond, GR; Berry, WR; de Wit, R; Armstrong, AJ; Eisenberger, MA; Tannock, IF. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urologic Oncology: seminars and original investigations. 2012;30:607-613.
(2012)
Abstract
Stewart, SB; Bañez, LL; Robertson, CN; Freedland, SJ; Polascik, TJ; Xie, D; Koontz, BF; Vujaskovic, Z; Lee, WR; Armstrong, AJ; Febbo, PG; George, DJ; Moul, JW. Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center. Journal of Urology. 2012;187:103-108.
(2012)
Abstract
Antonarakis, ES; Armstrong, AJ. Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. 2011;14:206-218.
(2011)
Abstract
Antonarakis, ES; Armstrong, AJ. Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. 2011;14:192-205.
(2011)
Abstract
Armstrong, AJ; Marengo, MS; Oltean, S; Kemeny, G; Bitting, RL; Turnbull, JD; Herold, CI; Marcom, PK; George, DJ; Garcia-Blanco, MA. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Molecular Cancer Research. 2011;9:997-1007.
(2011)
Abstract
Bitting, RL; Armstrong, AJ; George, DJ. Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?. Clinical Medicine Insights: Oncology. 2011;5:325-332.
(2011)
Abstract
Bitting, RL; Madden, J; Armstrong, AJ. Therapy for non-clear cell histologies in renal cancer. Current Clinical Pharmacology. 2011;6:169-180.
(2011)
Abstract
Pili, R; Häggman, M; Stadler, WM; Gingrich, JR; Assikis, VJ; Björk, A; Nordle, O; Forsberg, G; Carducci, MA; Armstrong, AJ. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. Journal of Clinical Oncology. 2011;29:4022-4028.
(2011)
Abstract
Sonpavde, G; Pond, GR; Berry, WR; de Wit, R; Eisenberger, MA; Tannock, IF; Armstrong, AJ. The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. Cancer. 2011;117:3963-3971.
(2011)
Abstract
Armstrong, AJ; Garrett-Mayer, E; de Wit, R; Tannock, I; Eisenberger, M. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clinical Cancer Research. 2010;16:203-211.
(2010)
Abstract
Armstrong, AJ; George, DJ. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. Prostate Cancer and Prostatic Diseases. 2010;13:108-116.
(2010)
Abstract
Armstrong, AJ; Netto, GJ; Rudek, MA; Halabi, S; Wood, DP; Creel, PA; Mundy, K; Davis, SL; Wang, T; Albadine, R; Schultz, L; Partin, AW; Jimeno, A; Fedor, H; Febbo, PG; George, DJ; Gurganus, R; De Marzo, AM; Carducci, MA. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clinical Cancer Research. 2010;16:3057-3066.
(2010)
Abstract
Armstrong, AJ; Tannock, IF; de Wit, R; George, DJ; Eisenberger, M; Halabi, S. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. European Journal of Cancer. 2010;46:517-525.
(2010)
Abstract
Armstrong, AJ; Febbo, PG. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. The Oncologist. 2009;14:816-827.
(2009)
Abstract
Armstrong, AJ; Halabi, S; de Wit, R; Tannock, IF; Eisenberger, M. The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer. Prostate Cancer and Prostatic Diseases. 2009;12:88-93.
(2009)
Abstract
Armstrong, AJ; Creel, P; Turnbull, J; Moore, C; Jaffe, TA; Haley, S; Petros, W; Yenser, S; Gockerman, JP; Sleep, D; Hurwitz, H; George, DJ. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clinical Cancer Research. 2008;14:6270-6276.
(2008)
Abstract
Armstrong, AJ; Garrett-Mayer, EL; Eisenberger, M. Re: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. Journal of National Cancer Institute. 2008;100:681-682.
(2008)
Abstract
Armstrong, AJ; George, DJ. New drug development in metastatic prostate cancer. Urologic Oncology: seminars and original investigations. 2008;26:430-437.
(2008)
Abstract
Chen, FL; Armstrong, AJ; George, DJ. Cell signaling modifiers in prostate cancer. The Cancer Journal. 2008;14:40-45.
(2008)
Abstract
Figlin, RA; Brown, E; Armstrong, AJ; Akerley, W; Benson, AB; Burstein, HJ; Ettinger, DS; Febbo, PG; Fury, MG; Hudes, GR; Kies, MS; Kwak, EL; Morgan, RJ; Mortimer, J; Reckamp, K; Venook, AP; Worden, F; Yen, Y. NCCN Task Force Report: mTOR inhibition in solid tumors. Journal of the National Comprehensive Cancer Network : JNCCN. 2008;6 Suppl 5:S1-20.
(2008)
Abstract
Ramiah, V; George, DJ; Armstrong, AJ. Clinical endpoints for drug development in prostate cancer. Current Opinion in Urology. 2008;18:303-308.
(2008)
Abstract
Armstrong, AJ; Febbo, PG; George, DJ; Moul, J. Systemic strategies for prostate cancer. Minerva Urologica e Nefrologica. 2007;59:11-25.
(2007)
Abstract
Armstrong, AJ; Garrett-Mayer, E; Ou Yang, YC; Carducci, MA; Tannock, I; de Wit, R; Eisenberger, M. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. Journal of Clinical Oncology. 2007;25:3965-3970.
(2007)
Abstract
Armstrong, AJ; Garrett-Mayer, ES; Yang, YC; de Wit, R; Tannock, IF; Eisenberger, M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clinical Cancer Research. 2007;13:6396-6403.
(2007)
Abstract
Mendiratta, P; Armstrong, AJ; George, DJ. Current standard and investigational approaches to the management of hormone-refractory prostate cancer. Reviews in Urology. 2007;9 Suppl 1:S9-S19.
(2007)
Abstract
Srinivasan, R; Armstrong, AJ; Dahut, W; George, DJ. Anti-angiogenic therapy in renal cell cancer. British Journal of Urology (BJU) International. 2007;99:1296-1300.
(2007)
Abstract
Armstrong, AJ; Carducci, MA. New drugs in prostate cancer. Current Opinion in Urology. 2006;16:138-145.
(2006)
Abstract
Armstrong, AJ; Eisenberger, M. Does gonadotropin-releasing-hormone agonist therapy for prostate cancer increase the risk of fracture?. Nature Reviews: Urology. 2006;3:246-247.
(2006)
Abstract
Armstrong, AJ; Carducci, MA. Advanced prostate cancer: the future. Canadian Journal of Urology. 2005;12 Suppl 2:42-47.
(2005)
Abstract
Armstrong, AJ; Carducci, MA. Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies. Current Oncology Reports. 2005;7:220-227.
(2005)
Abstract
Armstrong, AJ; Carducci, MA. Novel therapeutic approaches to advanced prostate cancer. Clinical Advances in Hematology and Oncology. 2005;3:271-282.
(2005)
Abstract
Nightingale, RW; Camacho, DL; Armstrong, AJ; Robinette, JJ; Myers, BS. Inertial properties and loading rates affect buckling modes and injury mechanisms in the cervical spine. Journal of Biomechanics. 2000;33:191-197.
(2000)
Abstract
Fukasawa, K; Zhou, R; Matten, WT; Armstrong, AJ; Daar, I; Oskarsson, M; Sathyanarayana, BK; Maclvor, L; Wood, TG; Vande Woude, GF. Mutagenic analysis of functional domains of the mos proto-oncogene and identification of the sites important for MAPK activation and DNA binding. Oncogene. 1995;11:1447-1457.
(1995)
Abstract
